Laurence Rulleau

Dr. Laurence Terrisse Rulleau is Chairwoman of the Board of Directors at Kainova Therapeutics and a managing partner at CTI Life Sciences Fund, where she has been involved in the fund’s investments since joining in 2014. CTI Life Sciences Fund is a Montreal-based venture capital fund investing in Canada, the United States, and Europe.

Before joining CTI, Dr Rulleau worked more than 10 years as a life sciences analyst covering the Canadian sector, with involvement in mergers and acquisitions as well as initial public offerings (IPOs). She previously served as CEO of HLA-G Technologies, a biotechnology start-up based in France, and later as Vice-President Business Development at Univalor, the technology transfer office of the Université de Montreal and its affiliated schools.

Dr. Rulleau holds a master’s degree in biology from the Université du Québec in Montreal (UQAM) and a Ph.D. from the Université de Montréal completed at Montreal Clinical Research Institute.